Psychiatric Side Effects of Chloroquine

2020 ◽  
Vol 81 (5) ◽  
Author(s):  
Florence Gressier ◽  
Céline Verstuyft ◽  
Laurent Becquemont ◽  
Bruno Falissard ◽  
Emmanuelle Corruble
Keyword(s):  
Side Effects ◽  
Psychiatric Side Effects

Burns in a suicide attempt related to psychiatric side effects of interferon

Burns ◽  
1998 ◽  
Vol 24 (6) ◽  
pp. 581-583 ◽  
Author(s):  
K. Fukunishi ◽  
H. Tanaka ◽  
J. Maruyama ◽  
H. Takahashi ◽  
H. Kitagishi ◽  
...  
Keyword(s):  
Side Effects ◽  
Suicide Attempt ◽  
Psychiatric Side Effects

Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

2007 ◽  
Vol 55 (3-4) ◽  
pp. 225-231 ◽  
Author(s):  
Marjolein Bannink ◽  
Durk Fekkes ◽  
Arthur R. Van Gool ◽  
Wim H.J. Kruit ◽  
Stefan Sleijfer ◽  
...  
Keyword(s):  
Side Effects ◽  
Tryptophan Metabolism ◽  
Interferon Α ◽  
Psychiatric Side Effects

P41 Psychiatric side effects of bilateral deep brain stimulation for movement disorders

Basal Ganglia ◽  
2011 ◽  
Vol 1 (2) ◽  
pp. 120-121
Author(s):  
M.O. Pinsker ◽  
F. Amtage ◽  
M. Berger ◽  
G. Nikkhah ◽  
L. Tebartz van Elst
Keyword(s):  
Deep Brain Stimulation ◽  
Side Effects ◽  
Brain Stimulation ◽  
Movement Disorders ◽  
Psychiatric Side Effects ◽  
Deep Brain

Psychiatric Side Effects

2019 ◽  
pp. 83-87
Author(s):  
Joshua Schimmel ◽  
Evren Burakgazi-Dalkilic ◽  
Hatice Burakgazi-Yilmaz
Keyword(s):  
Side Effects ◽  
Psychiatric Side Effects

Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse

2006 ◽  
Vol 21 (8) ◽  
pp. 551-562 ◽  
Author(s):  
Thomas A. Pagonis ◽  
Nikiforos V. Angelopoulos ◽  
George N. Koukoulis ◽  
Christos S. Hadjichristodoulou
Keyword(s):  
Side Effects ◽  
Anabolic Steroids ◽  
Linear Regression Analysis ◽  
Control Group ◽  
Time Interval ◽  
Psychological Consequences ◽  
Psychometric Instruments ◽  
Wide Range ◽  
Significant Difference ◽  
Psychiatric Side Effects

AbstractObjectiveThe objective of our study was to evaluate the psychological consequences of real-world AAS use in athletes abusing such agents, in comparison with a placebo and control group of comparable athletes, while correlating the severity of abuse with the side effects observed. The hypothesis tested by the study was that the use of AAS induces a wide range of psychological side effects whose impact and emergence is dependent upon the severity of the abuse.DesignThe study includes a substantial group of AAS abusing athletes and two more groups demographically similar to the first, one composed of athletes not using any substance and a placebo group. All athletes were stratified according to the severity of AAS abuse. Psychometric instruments were applied to all athletes in specific time intervals, dependent to the AAS abusers' regimens, providing us with a final psychological profile that was to be compared to the pre-study profile. All results were comparable (within and between groups) for statistically significant differences and correlated to the severity of the abuse. Homogeneity of all groups was safeguarded by random doping controls, monitoring of drug levels and analysis of all self obtained drugs by method of liquid chromatography/mass spectrometry. All athletes were provided with a common exercise and dietary regime, so common training and nutritional conditions were achieved.MethodsWe studied a cohort of 320 body-building, amateur and recreational athletes, of whom 160 were active users of AAS (group C), 80 users administering placebo drugs (group B) and 80 not abusing any substance (Group A). Group C athletes were stratified according to AAS abuse parameters, thus providing us with three subgroups of “light, medium and heavy abuse”. Athletes of groups A and B were included in a “no abuse” subgroup. The psychometric instruments used were the Symptoms Check List-90 (SCL-90) and the Hostility and Direction of Hostility Questionnaire (HDHQ). The psychometric evaluations took place within a time interval of 13 months. Statistical analysis was performed by using the Mann–Whitney/Wilcoxon two-sample non-parametric test (Kruskal–Wallis test for two groups) for data that were not normally distributed and Linear regression analysis was used to ascertain the correlation between severity of use and escalation of side effects.ResultsThe study showed a statistically significant increase in all psychometric subscales recorded in group C, and no statistically significant difference in group C and A. There was a significant increase in the scorings of group C for all subscales of SCL-90 and HDHQ. Correlation of abuse severity and side effects showed that there was a statistical significant increase in Δ values of all SCL-90 and HDHQ subscales that escalated from light abuse to medium and heavy abuse/consumption patterns.ConclusionsThe results of the study suggest that the wide range of psychiatric side effects induced by the use of AAS is correlated to the severity of abuse and the force of these side effects intensifies as the abuse escalates.

Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Azadeh Mesripour ◽  
Shahrzad Shahnooshi ◽  
Valiollah Hajhashemi
Keyword(s):  
Side Effects ◽  
Forced Swimming Test ◽  
Interferon Alfa ◽  
Interferon Α ◽  
High Dose ◽  
Antidepressant Effects ◽  
Immobility Time ◽  
Inflammatory Drugs ◽  
Swimming Test ◽  
Psychiatric Side Effects

AbstractBackgroundInterferon-α (IFNα) therapy causes psychiatric side effects, including depression that may result in poor compliance of therapy. It is important to find alternative therapies for the prevention of IFNα induced depression. Non-steroidal anti-inflammatory drugs (NSAIDs) have been useful in depressive disorder. Therefore the effects of celecoxib, ibuprofen, and indomethacin were evaluated following IFNα-induced depression in mice.MethodsMale albino mice weighing 26 ± 2 g were used. Depression was induced by IFNα (16 × 105 IU/kg, SC) for six consecutive days. Animals were first subject to the locomotor test, then the splash test and finally the forced swimming test (FST) on the 7th day. The NSAIDs were administered (IP) either one single dose before the test, or simultaneously with IFNα.Resultslocomotor activity was only impaired by ibuprofen high dose (75 mg/kg), thus it was not further evaluated. Following IFNα therapy depression-like behaviors were observed; significant changes during the splash test (grooming time 24 ± 7 sec vs. control 63 ± 7 sec), the FST (immobility time 166  ± 15 sec vs. control 128  ± 6 sec), and sucrose preference reduced to 64 ± 0.8%. The NSAIDs noticeably reduced the immobility time in FST, while grooming time was increased. Celecoxib and indomethacin single doses were effective while ibuprofen showed better antidepressant effects when it was administered along with IFNα.ConclusionsThe NSAIDs were able to prevent IFNα induced depression in mice. NSAIDs administration with IFNα does not interfere with clinical benefit effects of IFNα and they could also be useful to prevent IFNα psychiatric side effects, thus further clinical trials are suggested.

Interferon-α in Oncology Patients: Fewer Psychiatric Side Effects Than Anticipated

2008 ◽  
Vol 49 (1) ◽  
pp. 56-63 ◽  
Author(s):  
Marjolein Bannink ◽  
Wim H.J. Kruit ◽  
Arthur R. Van Gool ◽  
Stefan Sleijfer ◽  
Bronno van der Holt ◽  
...  
Keyword(s):  
Side Effects ◽  
Interferon Α ◽  
Oncology Patients ◽  
Psychiatric Side Effects

scholarly journals Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists

2009 ◽  
Vol 161 (5) ◽  
pp. 655-662 ◽  
Author(s):  
Helen Butler ◽  
Márta Korbonits
Keyword(s):  
Risk Factors ◽  
Weight Loss ◽  
Side Effects ◽  
Endocannabinoid System ◽  
Metabolic Effects ◽  
Beneficial Effects ◽  
Concise Review ◽  
Psychiatric Side Effects ◽  
Lipid Parameters ◽  
Cannabinoid Antagonists

The endocannabinoid system has emerged as a significant player in the control of energy balance and metabolism, through its direct central and peripheral effects, as well as via its interaction with other appetite-regulating pathways. There is mounting evidence that the endocannabinoid system is overactive in obesity and were it possible to safely dampen-down the elevated endocannabinoid tone, lipid and carbohydrate profiles could be improved and weight loss induced. The series of randomised clinical trials showed reproducible beneficial effects on weight, HbA1c and lipid parameters, in addition to other cardiovascular risk factors. However, to date, clinical developments have been halted because of psychiatric side effects. Although recent evidence has highlighted the importance of an appetite-independent, peripheral mode of action, it is still unclear whether selectively blocking the peripheral system could potentially solve the problem of the central side effects, which thus far has led to the demise of the cannabinoid antagonists as useful pharmaceuticals. In this concise review, we summarise the data on the metabolic effects of the cannabinoid pathway and its antagonists.

Sign in / Sign up

Export Citation Format

Share Document